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Abstract
Background: Poor adherence with prescribed asthma medication is a major barrier to positive treatment
outcomes. This study was designed to determine the effect of a once-daily administration of mometasone furoate
administered via a dry powder inhaler (MF-DPI) on treatment adherence compared with a twice-daily
administration.
Methods: This was a 12-week open-label study designed to mimic an actual clinical setting in patients ≥12 years
old with mild-to-moderate persistent asthma. Patients were randomized to receive MF-DPI 400 μg once-daily in
the evening or MF-DPI 200 μg twice-daily. Adherence was assessed primarily using the number of actual
administered doses reported from the device counter divided by the number of scheduled doses. Self-reports were
also used to determine adherence. Health-related quality of life, healthcare resource utilization, and days missed
from work or school were also reported.
Results: 1233 patients were randomized. The mean adherence rates, as measured by the automatic dose counter,
were significantly better (P < 0.001) with MF-DPI 400 μg once-daily in the evening (93.3%) than with MF-DPI 200
μg twice-daily (89.5%). Mean adherence rates based on self-reports were also significantly better (P < 0.001) with
MF-DPI 400 μg QD PM (97.2%) than with MF-DPI 200 μg twice-daily (95.3%). Adherence rates were lower in
adolescents (12-17 years old). Health-related quality of life improved by 20% in patients using MF-DPI once-daily in
the evening and by 14% in patients using MF-DPI twice-daily. Very few (<8%) patients missed work/school.
Conclusion: Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-
daily dosing regimen.
This trial was completed prior to the ISMJE requirements for trial registration.
Background
It is well established that inhaled corticosteroid (ICS)
therapy is the most effective treatment for patients with
persistent asthma[1,2]. Unfortunately, studies have
shown adherence with prescribed ICS therapy is poor,
with adherence rates generally thought to range from
30%-70% [3-6]. Low adherence is not only a major bar-
rier to achieving positive treatment outcomes in asthma
management, but may also be associated with an
increased risk of death due to asthma[7] and increased
health care costs, primarily through overuse of urgent
care, hospitalization, and unnecessary physician visits
[5,8,9].
Although further investigation on the effects of once-
daily dosing on ICS treatment adherence under more
controlled settings are needed, better adherence has
been observed in asthma[10] and other disease treat-
ments with once-daily dosing regimens than with twice-
daily regimens [11-13]. A case-control study by Guest et
al.[10] found that patients on twice-daily asthma treat-
ments who were switched to once-daily treatments were
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daily treatment. In addition, primary care management
costs were lower in patients who showed high adherence
after switching to once-daily treatment.
Mometasone furoate administered via a dry powder
inhaler (MF-DPI) has been shown to be effective in
treating asthma, as shown in comparative studies with
other ICSs [14-18]. Although early studies of MF-DPI in
mild and moderate asthma patients evaluated twice-
daily dosing regimens,[14,19] more recent studies have
demonstrated the comparability of MF-DPI 400 μg
once-daily in the morning to MF-DPI 200 μg twice-daily
[20,21] and the high efficacy of once-daily dosing in the
evening [22-25]. However, it should be noted that clini-
cal studies assessing adherence are often complicated by
a variety of factors, such as greater adherence rates due
to close patient monitoring, which results in adherence
rates not typical of clinical practice[13,26].
The primary objective of this study was to determine
the effect of once-daily versus twice-daily dosing of MF-
DPI on treatment adherence in a study designed to
mimic the actual clinical setting.
Methods
Patient Population
This multicenter study (143 sites in the United King-
dom) enrolled adolescents and adults aged 12 years or
older with mild-to-moderate persistent asthma, and a
diagnosis of asthma for at least 1 year. The study had
institutional review board approval at all sites, and all
patients provided informed consent before any study
procedures were conducted. The first visit date was Feb-
ruary 5, 2003, and the latest visit/contact date was Feb-
ruary 26, 2004. Eligible patients had been treated with
either beclomethasone dipropionate (BDP) hydrofluor-
oalkane (≤500 μg/d) or BDP chlorofluorocarbon (≤1000
μg/d) for ≥12 weeks, and had a stable BDP dosing regi-
men for ≥4 weeks immediately before study entry. The
inclusion of patients who used BDP as their prior ICS
therapy was justified because BDP was the ICS pre-
scribed most commonly in the UK when the study was
conducted, thereby providing a patient population as
large and homogeneously-treated as possible. Eligible
patients had no clinically significant disease that would
interfere with study evaluations, and female patients of
childbearing potential were required to use medically
accepted birth control. Patients who required ventilator
support for respiratory failure due to asthma within the
previous 5 years or were hospitalized within the pre-
vious 3 months because of asthma were ineligible.
Study Protocol
This was a 12-week, open-label study designed to mimic
an actual clinical setting. Visits took place every 4
weeks. Patients were randomized to receive either MF-
DPI 400 μg once-daily in the evening or MF DPI 200 μg
twice-daily from inhalers measuring 220 μg/actuation
and delivering 200 μg/inhalation. Assessments were
m a d ea tb a s e l i n e ,a n dw e e k s4 ,8 ,a n d1 2 .P a t i e n t sw e r e
instructed in inhaler use and peak flow measurement to
demonstrate proficiency and received salbutamol for
rescue medication. Optional diary cards were provided
to record adverse events (AEs), use of rescue medica-
tion, and changes in concomitant medication between
visits. Completed diary comment cards were reviewed at
all subsequent visits. Following increases in asthma
symptoms from baseline, patients used the peak flow
meter to obtain an objective measure of asthma worsen-
ing. Daily use of the peak flow meter was not required
to more closely mimic real-life practice. Patients were
also instructed to follow an asthma action plan based on
t h e i rp e r s o n a lb e s tp e a kf l o wa tt h ef i r s tv i s i t .I fp e a k
flow was <75% personal best for 2 consecutive days, the
patient was required to consult the investigator. Recom-
mended clinical practice guidelines were also provided
to investigators.
Primary Evaluation
Adherence was calculated as the number of adminis-
tered doses (as determined by device counter number)
times 100 divided by the number of scheduled doses.
Data were not included for analysis if invalid (eg, gross
misuse of device, missing treatment end dates, or device
malfunction). Examples of gross misuse of the device
included failure to twist the cap when opening/closing
the inhaler, or removing and replacing the inhaler cap
more than once without taking a dose. If a device was
not returned, it was assumed to have been unused.
Secondary Evaluations
Secondary evaluations included measurements of adher-
ence based on the patients’ or their guardians’ reports of
adherence, regardless of the actual counter readings.
The physician’s assessment of a therapeutic response
was documented at all visits. Health-related quality of
life (HRQOL) was assessed using the Integrated Thera-
peutics Group Asthma Short Form (ITG-ASF), a brief
and reliable disease-specific questionnaire[27]. For this
study, the ITG-ASF was administered at baseline and
w e e k1 2 .T h eI T G - A S Fd o e sn o th a v ead e r i v a t i o no f
total score for children, therefore, only HRQOL data
obtained from subjects at least 16 years old are reported.
Healthcare resource utilization and the number of days
missed from work or school were recorded at all visits.
Safety Evaluation
Safety assessments included reporting of AEs at all vis-
its. An abbreviated physical exam and vital signs (heart,
lungs, weight, blood pressure, pulse, and breath rates)
were performed on visits 1 and 4. An evaluation of
asthma worsening was performed at all visits, with
asthma worsening being defined as an increased use of
Price et al. BMC Pulmonary Medicine 2010, 10:1
http://www.biomedcentral.com/1471-2466/10/1
Page 2 of 9rescue medication (>12 inhalations on 2 consecutive
days), a decrease in peak flow of >25% on 2 consecutive
days, or clinical asthma exacerbations (unscheduled doc-
tor’s visit, hospitalization, ER visit, and/or use of addi-
tional asthma medications other than short-acting
b-agonists).
Statistical Analyses
A total of 1300 patients, or 650 per treatment group,
were targeted for inclusion in this study, allowing a 90%
power to detect a difference of at least 10% between dis-
tributions of adherence rates. The study was not powered
to test differences in mean adherence. A sample of this
size also allowed a sub-group analysis, with a 90% power
to detect positive correlations of more than 0.15 between
the level of adherence and the total ITG-ASF within each
group (0.05 significance level). The Kolmogorov-Smirnov
test was used to determine the significance of observed
differences in the distribution of adherence rates between
the 2 treatment groups. The Pearson correlation coeffi-
cient was used to analyze the correlation between adher-
ence and changes in the ITG-ASF score. The chi-square
test was used to analyze health care utilization and num-
ber of missed days of school/work. An analysis of var-
iance (ANOVA) was used to extract sources of variation
by treatment and center.
Results
Patients
A total of 1233 patients were randomized to treatment;
611 patients in the MF-DPI 400 μg once-daily group
and 622 patients in the MF-DPI 200 μgt w i c e - d a i l y
group (Figure 1). The primary analysis of adherence
excluded subjects with invalid data, subjects missing
treatment end dates, and subjects who reported device
issues. Adherence data based on the device counter was
analyzed for 557 patients in the MF-DPI 400 μgo n c e -
daily group and 578 patients in the MF-DPI 200 μg
twice-daily group. Similar proportions of subjects in the
2 treatment groups returned all 6 canisters of study
medication: 92.0% (469/510) in the MF-DPI 400 μg
once-daily group and 90.7% (478/527) in the MF-DPI
200 μg twice-daily group. No statistical differences were
present between the randomized groups at baseline in
age, sex, race, and weight, or in duration of disease (sea-
sonal or allergic rhinitis or asthma). Baseline demo-
graphics are shown in Table 1.
Primary Endpoint (Adherence)
The primary endpoint of adherence as measured by
device counter was 93.3% (95% CI: 91.6-94.9) for the
once-daily group and 89.5% (95% CI: 88.1-90.8) for the
twice-daily group; the maximum difference in distribu-
tion of adherence rates results was significant at P <
0.001 (Figure 2). As measured by patient self-reports,
adherence was 97.2% (95% CI: 96.4-97.9) for the once-
daily group and 95.3% (95% CI: 94.4-96.2) for the twice-
daily group, and the difference in distribution of the
adherence results was significant at P < 0.001 (Figure 2).
In the subgroup of patients who received and returned
all 6 canisters of study medication, adherence was 96.4%
(95% CI: 95.5-97.3) for the once-daily group (n = 469),
and 91.8% (95% CI: 91.0-92.7) for the twice-daily group
(n = 478; P < 0.001). Adherence was numerically lower
for 12-18 year olds (once-daily group = 80.8% [95% CI:
64.1-97.5]), twice-daily group = 87.3% [95% CI: 81.2-
92.4]); these patients comprised only 3% of the popula-
tion, and statistical analysis was not done because there
were very few patients in this subgroup. The rates of
adherence for female and male patients were similar to
each other and to the overall population.
Secondary Endpoints
Using 2-way ANOVA with treatment and site effects, 52%
of individual patients showed improvement in the physi-
cian’s evaluation of therapeutic response on a scale of 1-5
from baseline, with 1 representing much improved and 5
representing much worse (P = not significant; Figure 3).
With regard to HRQOL as measured by ITG-ASF scores
(assessed in subjects at least 16 years of age), both groups
improved relative to baseline (Figure 4). No significant
correlation existed between HRQOL and adherence. How-
ever, there was a numerically greater increase in HRQOL
in the once-daily group (20%) relative to the twice-daily
group (14%), although the difference was not statistically
significant (P = 0.08). Regarding healthcare utilization, few
patients had missed days of work or school (once-daily
group = 9; twice-daily group = 10) or unscheduled health
visits (once-daily group = 37; twice-daily group = 33). No
significant difference was seen between treatment groups
(P ≥ 0.48).
Safety Evaluation
T h en a t u r ea n do c c u r r e n c eo fA E sw e r es i m i l a rt ot h o s e
reported in other studies of ICS [28-30]. AEs for the most
part were not considered treatment related, and were
mild-to-moderate in severity (Table 2). Only 6 patients
reported severe treatment-related AEs; 1 patient each with
mouth ulceration and oral candidiasis in the MF-DPI 400
μg once-daily group, and 1 patient each with headache,
tongue disorder, oral candidiasis, and hypoglycemia in the
MF-DPI 200 μg twice-daily group. Fifty-five patients (23 in
the once-daily group and 32 in the twice-daily group) dis-
continued treatment owing to AEs, and were not analyzed.
An additional 38 patients had treatment interrupted owing
to AEs. Two patient deaths were reported (1 due to cardi-
orespiratory arrest and 1 due to lung carcinoma); neither
was considered treatment related.
Discussion
Mean adherence rates, as measured by the automatic
dose counter, were found to be significantly better for a
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administration. Once-daily treatment with MF-DPI also
significantly improved mean adherence rates based on
patient self-reports compared with twice-daily MF-DPI,
as well as mean adherence rates based only on those
patients who received and returned all 6 canisters of
study medication.
Despite the significant differences in mean adherence,
we found no significant differences in clinical outcomes.
This is likely due to the unusually high rates of adher-
ence observed in both study groups (89%-93%). The
adherence rates in this study are much higher than the
rates previously reported in the literature (30% to 70%),
[5,6] and may have been influenced by the constraints
of the clinical trial in terms of attention and study parti-
cipants. Direct interaction between physicians and
asthma patients (or their parents/caregivers) has been
shown to improve adherence. In one study, a treatment
group receiving direct feedback from clinicians had an
a d h e r e n c er a t eo fa p p r o x i m a t e l y6 0 %a tt h ef i r s tv i s i t ,
which then increased and remained above 70% at each
weekly visit for the duration of the 10-week study. In
the control group receiving usual asthma care, adher-
ence declined from approximately 50% at the first
weekly visit to <30% at the final weekly visit[4]. In addi-
tion, patients who volunteer to participate in a study
m a yb em o r ew i l l i n gt oc o m p l yw i t hat r e a t m e n t
regimen.
This study was designed to prevent some of these
issues. Patients were not informed that device dose
counts were checked at each visit. The study also tried
to decrease aspects of a clinical study that would pro-
mote adherence and tried to mimic asthma management
in a typical clinical practice. Doctor visits were limited
to once a month, and patients were not required to
keep daily records of symptoms or peak flow. In addi-
tion, in accordance with clinical practice guidelines,[1,2]
patients were given an “Asthma Action Plan” to help
guide them in self-managing their symptoms.
A limitation of this study may be its duration. Treat-
ment adherence in clinical trial settings does not typi-
cally reflect normal rates of adherence until a more
prolonged period has passed[31]. One long-term study
of children and adolescents (ages 7-16 y) with mild
asthma treated with once- or twice-daily doses of ICS
found that adherence rates significantly declined follow-
ing 3 months of treatment and continued to decline by
more than 50% in both treatment groups after 9 months
Figure 1 Subject Disposition. MF-DPI = mometasone furoate administered via a dry powder inhaler.
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Page 4 of 9Table 1 Baseline Demographics of Patients
MF-DPI 400 μgQ DP M
(n = 611)
MF-DPI 200 μg BID
(n = 622)
Mean age, y 50.9 50.2
Patients by age, n (%)
12 to <18 y 21 (3) 22 (4)
18 to <65 y 444 (73) 465 (75)
≥65 y 146 (24) 135 (22)
Sex
Women/men 338/273 357/265
Race
White/nonwhite 607/4 615/7
Mean body weight, kg 77.3 76.7
n = 599 n = 614
Mean duration of SAR, y 17.2 19.2
n = 238 n = 235
Mean duration of PAR, y 19.7 20.9
n = 163 n = 164
Mean duration of asthma, y 16.4 16.2
n = 611 n = 622
BID = twice-daily; MF-DPI = mometasone furoate administered via a dry powder inhaler; PAR = perennial allergic rhinitis; QD PM = once-daily in the evening; SAR
= seasonal allergic rhinitis.
Figure 2 Mean adherence to treatment. Adherence was calculated as administered doses divided by scheduled doses × 100, as measured by
dose counter and patient self-report. Error bars represent standard error of the mean. *P < 0.001. BID = twice-daily; MF-DPI = mometasone
furoate administered via a dry powder inhaler; QD = once-daily.
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Page 5 of 9[31]. Thus, it is possible that given a longer duration,
the adherence rates observed in this study would
decrease to lower levels. Furthermore, this study did not
use direct measures of adherence, which are not practi-
cal or reliable for large numbers of patients in ordinary
settings. It is not possible to document whether patients
were actually taking their medication correctly or fol-
lowing their dosing regimen. The patients may have
taken multiple doses at the same time, or patients may
have actuated their inhaler but not taken the medica-
tion. In addition, since patients were not required to
keep daily diary records, their self-reports were based
largely on memory, which may have resulted in erro-
neous adherence estimates.
The literature is lacking clear documentation on the
impact of once- vs twice-daily dosing. However, reliable
measurements of medication use were obtained in a
study that evaluated adherence by patients with mild
asthma randomized to treatment with oral montelukast
10 mg once-daily (n = 189) or inhaled fluticasone pro-
pionate 88 μg twice-daily (n = 191)[32]. The montelu-
kast pill boxes and fluticasone inhalers used in the study
had electronic monitoring devices to record medication
use continuously over 12 weeks of placebo-controlled
double-blind treatment and 36 weeks of open-label
treatment with no placebo. Adherence rates with once-
daily montelukast and twice-daily fluticasone were
77.5% and 70.2%, respectively (P < 0.0001), during dou-
ble-blind treatment and 71.4% and 63.9%, respectively
(P = 0.001), during open-label treatment. Although
adherence rates in the study were less than prescribed,
it was found that adherence with once-daily treatment
was superior to adherence with twice-daily treatment.
This difference could be related to the fact that monte-
lukast is an oral medication and fluticasone is an inhaled
medication.
Despite limitations of the present study, the observed
efficacy results suggest that patients were taking their
medication and that their asthma was more adequately
treated than it had been prior to randomization. Both
treatment groups showed improved HRQOL, and over
half of all patients in both treatment groups were rated
as having an improved therapeutic response from base-
line. Very few patients had unscheduled office or home
Figure 3 Physician’s evaluation of therapeutic response. Response expressed as mean relative to baseline. P = not significant. MF-DPI =
mometasone furoate administered via a dry powder inhaler.
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Page 6 of 9visits or reported missed days from work or school. The
differences in adherence between the once-daily and
twice-daily groups were statistically significant, yet they
were small and not correlated with improvements in
HRQOL. Moreover, once-daily dosing in adolescents
was associated with numerically lower adherence than
twice-daily dosing, although this difference was not sta-
tistically significant.
Asthma therapy is complex, and treatment dosing fre-
quency is one of many factors that affect adherence.
Both groups in the present study had high rates of
adherence, which suggests that factors including the
physician-patient relationship, medical costs, and patient
beliefs regarding illness and medication strongly influ-
ence adherence in clinical practice[33,34]. According to
the model proposed by Horne et al,[33] treatment
adherence is related to a patient’s perception of illness.
Strong correlations have been observed between (1)
nonadherence and patients who believed treatment
medication was unnecessary or had concerns of adverse
effects and (2) greater adherence and patients who
believed their asthma was of greater severity[33]. It is
essential to individualize therapy to meet patient needs
by identifying nonadherence and the causes of nonad-
herence for individual patients, as recommended in a
recent paper by the International Primary Care Respira-
tory Group.[35]
One indication for prescribing once-daily asthma ther-
apy is for patients who are likely to experience difficul-
ties with twice-daily therapy. It is clear that most
patients randomized to twice-daily treatment in the pre-
sent study did not find this regimen to be a barrier to
adherence, although overall adherence rates in clinical
practice appear to be significantly lower than adherence
rates in this trial. Further studies are needed to deter-
mine the degree to which twice-daily dosing might
erode adherence over time, and to measure the effects
of switching to a once-daily regimen for those patients
who find that twice-daily therapy is a barrier to adher-
ence. Although for some patients it is also possible that
dosing frequency may have an impact on treatment effi-
cacy, given that a once-daily medication has only one
trough per day, whereas a twice-daily medication has
two troughs per day. In the present study, however, the
once- and twice-daily doses of MF-DPI had similar
efficacy.
Table 2 Incidence of Treatment-Related AEs Reported by ≥1% of Patients
MF-DPI 400 μgQ DP M
(n = 611)
MF-DPI 200 μg BID
(n = 622)
Patients reporting any AE, n (%) 85 (14) 109 (18)
Headache 10 (2) 12 (2)
Dysphonia 3 (<1) 9 (1)
Mouth dry 12 (2) 11 (2)
Mouth ulceration 5 (1) 1 (<1)
Candidiasis, oral 9 (1) 16(3)
Pharyngitis 16 (3) 15 (2)
Upper respiratory tract infection 5 (1) 0
Cough 2 (<1) 6 (1)
Hoarseness 4 (1) 5 (1)
Throat dry 11 (2) 3 (<1)
Rash 0 4 (1)
AE = adverse event; BID = twice-daily; MF-DPI = mometasone furoate administered via a dry powder inhaler; QD PM = once-daily in the evening.
Figure 4 Mean percent change in HRQOL. Changes from
baseline in HRQOL were measured by ITG-ASF scores in subjects
≥16 years of age. HRQOL = health-related quality of life; ITG-ASF =
Integrated Therapeutics Group-Asthma Short Form; MF-DPI =
mometasone furoate administered via a dry powder inhaler; QD =
once-daily.
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Page 7 of 9Conclusion
Overall adherence to treatment with mometasone furo-
ate dry powder inhaler was very high in this study, with
a statistically greater mean adherence rate using a once-
daily dosing regimen versus a twice-daily dosing
regimen.
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